This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Assertio (ASRT) Could Beat Earnings Estimates Again
by Zacks Equity Research
Assertio (ASRT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of Zoetis' (ZTS) key drugs like Apoquel, Cytopoint, Simparica Trio, Librela and Solensia are expected to have driven sales, partially offset by lower sales of livestock, cattle, poultry and swine products.
Investors Heavily Search Assertio Holdings, Inc. (ASRT): Here is What You Need to Know
by Zacks Equity Research
Assertio (ASRT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Assertio (ASRT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Assertio (ASRT) closed the most recent trading day at $4.18, moving +1.95% from the previous trading session.
Assertio (ASRT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Assertio (ASRT) closed at $4.02, marking a +0.25% move from the previous day.
Assertio (ASRT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Assertio (ASRT) closed at $4.06 in the latest trading session, marking a +1.25% move from the prior day.
Zacks Industry Outlook Highlights Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer Therapeutics
by Zacks Equity Research
Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer Therapeutics are part of the Zacks Industry Outlook article.
5 Stocks to Buy as the Drug Industry Bets Big on Innovation
by Kinjel Shah
Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. DYN, SLN, TCRT, ASRT and ACER may prove to be good additions to one's portfolio.
Corcept (CORT) Rides on Robust Korlym Sales, High Reliance a Woe
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since approval. However, sole dependence on Korlym for revenues remains a headwind.
Assertio (ASRT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Assertio (ASRT) closed the most recent trading day at $4.22, moving +1.44% from the previous trading session.
Take the Zacks Approach to Beat the Market: Boeing, Halliburton, Starbucks in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Are Medical Stocks Lagging Assertio (ASRT) This Year?
by Zacks Equity Research
Here is how Assertio (ASRT) and Liquidia Technologies, Inc. (LQDA) have performed compared to their sector so far this year.
ASRT vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
ASRT vs. ZTS: Which Stock Is the Better Value Option?
Ensign Group (ENSG) Rises 30% in 6 Months: More Room to Run?
by Zacks Equity Research
Ensign Group (ENSG) is well-poised for improvement on growing revenues derived from catering to patients under Medicaid and Medicare programs. Solid cash flows are other tailwinds.
Is Assertio (ASRT) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
After Golden Cross, Assertio (ASRT)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
Are Medical Stocks Lagging Assertio (ASRT) This Year?
by Zacks Equity Research
Here is how Assertio (ASRT) and Liquidia Technologies, Inc. (LQDA) have performed compared to their sector so far this year.
ASRT or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ASRT vs. ZTS: Which Stock Is the Better Value Option?
Ensign Group (ENSG) Facility Buyout to Boost Colorado Foothold
by Zacks Equity Research
Ensign Group (ENSG) acquires two skilled nursing facilities in Colorado that are likely to grow its healthcare portfolio and solidify its nationwide presence.
Is Liquidia Technologies (LQDA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Liquidia Technologies, Inc. (LQDA) and Assertio (ASRT) have performed compared to their sector so far this year.
Xeris (XERS), Horizon to Develop Ready-to-Use Teprotumumab
by Zacks Equity Research
Xeris Biopharma (XERS) enters into a research collaboration with Horizon Therapeutics to develop a ready-to-use variant of teprotumumab to treat thyroid eye disease.
ASRT vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
ASRT vs. ZTS: Which Stock Is the Better Value Option?
Should Value Investors Buy Assertio (ASRT) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Jazz Pharma's (JAZZ) Gets FDA Nod for Rylaze's New Dosing Option
by Zacks Equity Research
Jazz Pharma (JAZZ) gets FDA approval for an MWF intramuscular (IM) dosing schedule for Rylaze to treat acute lymphoblastic leukemia or lymphoblastic lymphoma with hypersensitivity to asparaginase.